NAUT

Nautilus Biotechnology, Inc. (NAUT) - Q1 2026 Filing Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended March 31, 2026. Nautilus Biotechnology, Inc. is a development-stage life sciences company focused on the Nautilus Voyager™ platform, a proteomics technology utilizing Iterative Mapping to quantify single, intact protein molecules. The company has not yet commercialized any products and has generated no revenue since inception. It is classified as a smaller reporting company and is listed on The Nasdaq Stock Market LLC.

Key Financial Metrics

Note: The company reported $143.4 million in total cash, cash equivalents, and investments (including long-term investments) as of March 31, 2026.

Material Changes vs. Prior Period

• Expense Reductions: Total operating expenses decreased by 14% ($2.7 million) compared to Q1 2025.
  • R&D Expenses: Decreased by 16% ($1.8 million), primarily due to a $1.0 million reduction in salaries and benefits following a workforce reduction in Q1 2025, and lower stock-based compensation.
  • SG&A Expenses: Decreased by 12% ($0.9 million), driven by a $0.6 million decrease in stock-based compensation and lower salaries.
• Interest Income: Decreased by 35% ($0.8 million) to $1.4 million, attributed to lower investment balances and decreased yield rates.
• Net Loss Improvement: Net loss narrowed by 12% ($1.9 million) to $14.7 million.
• Investment Activity: The company generated $14.2 million in net cash from investing activities, primarily from proceeds from maturities of securities ($25.8 million) offset by purchases of securities ($11.1 million).

Guidance, Outlook, and Risks

• Commercialization Timeline:
  • Early Access Program: Launched in January 2026 with target-specific service offerings for the microtubule-associated protein tau (Tau). Management does not anticipate material revenue from these activities.
  • Commercial Launch: Expected in late 2026 with pre-orders for the Voyager instrument and Tau assay. Instrument installations at customer sites are expected to begin in early 2027.
  • Broadscale Capabilities: General availability anticipated in the first half of 2027.
• Liquidity: Management believes existing cash, cash equivalents, and short-term investments ($95.9 million in current assets) are sufficient to fund operations for at least the next 12 months. The company expects to incur significant losses for the foreseeable future and will require additional capital to fund development and commercialization.
• Key Risks:
  • Development Risk: The Nautilus Voyager platform remains in development; there is no assurance it will be commercially viable or achieve market acceptance.
  • Supply Chain: Dependence on single-source suppliers for critical components and reagents.
  • Regulatory: Potential future regulation by the FDA if products are marketed for clinical diagnostic use.
  • Market Volatility: The company previously received a Nasdaq deficiency notice regarding minimum bid price in May 2025 but regained compliance in November 2025. Continued volatility poses a delisting risk.

Investor Verification Checklist

• Verify the progress of the Early Access Program and the number of collaborators engaged since the January 2026 launch.
• Monitor the company's cash burn rate relative to the stated 12-month liquidity runway, especially as commercialization costs rise in late 2026.
• Assess the status of manufacturing partnerships and supply chain stability for the Voyager instrument and consumables.
• Review the stock price relative to the Nasdaq minimum bid price requirement ($1.00) to ensure continued listing compliance.
• Track the timeline for the late 2026 commercial launch and any potential delays in instrument installations scheduled for early 2027.